A case of neuromyelitis optica spectrum disorder with coexisting systemic lupus erythematosus.
AQP-4 antibodies
Neuromyelitis optica
SLE
longitudinal extensive transverse myelitis
optic neuritis
Journal
Journal of community hospital internal medicine perspectives
ISSN: 2000-9666
Titre abrégé: J Community Hosp Intern Med Perspect
Pays: United States
ID NLM: 101601396
Informations de publication
Date de publication:
21 Jun 2021
21 Jun 2021
Historique:
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Neuromyelitis Optica or Devic disease is changed to Neuromyelitis Optica spectrum disorder to include more diverse neurological and autoimmune manifestations. This is a severe relapsing autoimmune demyelinating disorder commonly affecting the optic nerve and spinal cord. It has been reported as either the first manifestation of SLE or as a coexisting condition with other autoimmune disorders commonly included but not limited to SLE and SS. We discussed a case of a 49-year-old female patient who was initially presented with a left-sided weakness that rapidly progressed to quadriparesis and bladder dysfunction within a few days. She had positive autoimmune serology tests for SLE posing a diagnostic challenge as SLE is associated with neurological manifestations. Due to a lack of definitive diagnostic criteria for SLE, presence of AQP-4 antibodies in CSF, and evidence of longitudinal extensive transverse myelitis in MRI cervical spine, we conclude that she has Neuromyelitis Optica spectrum disorder with probable SLE. It is possible that she may develop more signs and symptoms of SLE with time and will need close follow up. Timely diagnosis and prompt treatment are vital to decrease morbidity and mortality, as done in our case. The patient was started on high-dose steroids with significant improvement in her symptoms. These patients may need early treatment with plasmapheresis and long-term follow-up with immunotherapy to prevent relapse. There are few case reports in the literature, and more information is needed to understand and better diagnose NMO with coexisting SLE.
Identifiants
pubmed: 34211664
doi: 10.1080/20009666.2021.1915533
pii: 1915533
pmc: PMC8221122
doi:
Types de publication
Journal Article
Langues
eng
Pagination
531-535Informations de copyright
© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group on behalf of Greater Baltimore Medical Center.
Déclaration de conflit d'intérêts
No potential conflict of interest was reported by the author(s).
Références
N Engl J Med. 2019 Aug 15;381(7):614-625
pubmed: 31050279
Neurology. 2012 Feb 28;78(9):665-71; discussion 669
pubmed: 22302543
Arch Neurol. 2012 Sep;69(9):1176-80
pubmed: 22733096
Acta Neuropathol Commun. 2019 Jul 11;7(1):112
pubmed: 31296268
Ann Neurol. 2006 Mar;59(3):566-9
pubmed: 16453327
Neurosci Lett. 2001 Jul 13;307(2):131-3
pubmed: 11427318
Arch Neurol. 2008 Jan;65(1):78-83
pubmed: 18195142
J Exp Med. 2005 Aug 15;202(4):473-7
pubmed: 16087714
Medicine (Baltimore). 2017 Oct;96(40):e7958
pubmed: 28984755
Arthritis Care Res (Hoboken). 2017 Jul;69(7):1069-1075
pubmed: 27696784
J Neuroinflammation. 2008 May 29;5:22
pubmed: 18510734
Lupus. 2006;15(2):107-9
pubmed: 16539283
J Rheumatol. 2004 Feb;31(2):280-5
pubmed: 14760797
Neurology. 2015 Jul 14;85(2):177-89
pubmed: 26092914